Invitation to Oncopeptides’ investor webcast following positive glioblastoma data
STOCKHOLM — October 9, 2026 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, invites investors, analysts, and media to an audiocast and telephone conference on Monday, October 12, 2026, at 08:00 CET.
Earlier today, Oncopeptides announced positive interim data from the ongoing Window-of-Opportunity study, OP-701 (INSULA), demonstrating that the company’s proprietary Peptide Drug Conjugate (PDC) platform successfully penetrates the human blood-brain barrier in patients with glioblastoma.
Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on October 12 at 08:00 CET.
The presentation will be hosted by CEO Sofia Heigis and CFO Henrik Bergentoft, who will provide further details on the findings and answer questions. The webcast will be held in English.
Information for participants
If you wish to participate via webcast, please use the link below.
https://events.inderes.com/oncopeptides/investor-update-2026
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/oncopeptides/investor-update-2026/dial-in
A recording of the webcast and presentation slides will be made available afterwards on Oncopeptides’ website, www.oncopeptides.com.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68
About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.
Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.
The company was founded in 2000, has about 70 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com
Invitation to Oncopeptides’ investor webcast following positive glioblastoma data
